• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Cymabay Therapeutics (NQ: CBAY )

    N/A UNCHANGED
    Last Price Updated: 4:00 PM EDT, Mar 21, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open -
    Bid (Size) 32.36 (5)
    Ask (Size) 32.49 (100)
    Prev. Close 32.48
    Today's Range N/A - N/A
    52wk Range 17.47 - 32.49
    Shares Outstanding 84,677,939
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    CymaBay Therapeutics Inc. (NASDAQ: CBAY) is a Stock Spotlight on 3/21
    Via Investor Brand Network
    Gilead's Aggressive Push Beyond HIV Treatments - Plans To Increase Cancer-Focused CAR-T Treatment Production
    Gilead Sciences plans to quadruple cell therapy cancer treatment production by 2026. With a focus on CAR-T treatments like Yescarta and Tecartus, Gilead aims to diversify into oncology. Anticipating a... 
    Via Benzinga

    Performance

    More News

    Read More
    Top 3 Health Care Stocks That Are Ticking Portfolio Bombs
    Via Benzinga
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CymaBay Therapeutics, Inc. (Nasdaq – CBAY), Everi Holdings Inc. (NYSE – EVRI), Sterling Check Corp. (Nasdaq – STER), Societal CDMO Check Corp. (Nasdaq – SCTL)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    CymaBay Therapeutics Inc. (NASDAQ: CBAY) is a Stock Spotlight on 2/21
    Via Investor Brand Network
    CymaBay Therapeutics Inc. (NASDAQ: CBAY) is a Stock Spotlight on 2/13
    Via Investor Brand Network
    CymaBay Therapeutics Inc. (NASDAQ: CBAY) is a Stock Spotlight on 1/25
    Via Investor Brand Network
    CYMABAY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CymaBay Therapeutics, Inc. - CBAY
    From Kahn Swick & Foti, LLC
    Via Business Wire
    Analysts see over 50% gains in these 2 mid-cap biotech stocks
    Via MarketBeat
    Topics Artificial Intelligence
    Exposures Artificial Intelligence COVID-19
    CymaBay Therapeutics Deal May Not Be Needle Moving For $100B Valued Gilead, But Acquisition Is Reasonably Priced: Analyst
    Via Benzinga
    Fear & Greed Index Remains In 'Extreme Greed' Zone Ahead Of Inflation Data; Dow Hits Record high
    Via Benzinga
    Topics Economy Stocks
    Exposures Interest Rates US Equities
    6 Analysts Have This to Say About CymaBay Therapeutics
    Via Benzinga
    Recap: CymaBay Therapeutics Q3 Earnings
    Via Benzinga
    Dow Surges Over 150 Points; Gilead Sciences To Acquire CymaBay Therapeutics For $4.3B
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Dow Up Triple Digits, Hits Fresh Highs
    Via Talk Markets
    Topics Economy Stocks
    Exposures Interest Rates US Equities
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CymaBay Therapeutics, Inc. (Nasdaq – CBAY), Masonite International Corporation (NYSE – DOOR), ZeroFox Holdings, Inc. (Nasdaq – ZFOX), RayzeBio, Inc. (Nasdaq – RYZB)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    Why is CymaBay (CBAY) Stock Up 25% Today?
    Via InvestorPlace
    CymaBay Therapeutics, ContextLogic, Snap And Other Big Stocks Moving Higher On Monday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Health Care Company Gilead Sciences Announces Acquisition of CymaBay Therapeutics
    Via Benzinga
    CBAY Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of CymaBay Therapeutics, Inc. Is Fair to Shareholders
    From Halper Sadeh LLC
    Via Business Wire
    Drugmaker Gilead Sciences Scoops Up Liver-Disease Focused CymaBay Therapeutics For $4.3B
    Via Benzinga
    Exposures Product Safety
    CymaBay Stock Rockets After Gilead Sciences Unveils $4.3 Billion Acquisition
    Via Investor's Business Daily
    Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics
    From Gilead Sciences, Inc.
    Via Business Wire
    Why CymaBay Morphed From Dollar Stock To Biotech Rocket
    Via Investor's Business Daily
    Raymond James Maintains Strong Buy Rating for CymaBay Therapeutics: Here's What You Need To Know
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.